Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective study analyzed the BIOREP registry data of patients treated...

Full description

Bibliographic Details
Main Authors: Martina Kojanova, Jan Hugo, Barbora Velackova, Petra Cetkovska, Jorga Fialova, Tomas Dolezal, Martin Tichy, Spyridon Gkalpakiotis
Format: Article
Language:English
Published: Taylor & Francis Group 2022-08-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
il-17 inhibitors
brodalumab
ixekizumab
secukinumab
real-world
biological therapy
registries
biorep
Online Access:http://dx.doi.org/10.1080/09546634.2022.2082354

Internet

http://dx.doi.org/10.1080/09546634.2022.2082354

Similar Items